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ABSTRACT
Age-dependent changes in skeletal growth are important for regulating skeletal expansion and determining peak bone mass. However,
how G protein–coupled receptors (GPCRs) regulate these changes is poorly understood. Previously, we described a mouse model
expressing Rs1, an engineered receptor with high basal Gs activity. Rs1 expression in osteoblasts induced a dramatic age-dependent
increase in trabecular bone with features resembling fibrous dysplasia. To further investigate how activation of the Gs-GPCR pathway
affects bone formation at different ages, we used the tetracycline-inducible system in the ColI(2.3)
þ/Rs1
þ mouse model to control
the timing of Rs1 expression. We found that the Rs1 phenotype developed rapidly between postnatal days 4 and 6, that delayed
Rs1 expression resulted in attenuation of the Rs1 phenotype, and that the Rs1-induced bone growth and deformities were markedly
reversed when Rs1 expression was suppressed in adult mice. These findings suggest a distinct window of increased osteoblast
responsiveness to Gs signaling during the early postnatal period. In addition, adult bones encode information about their normal shape
and structure independently from mechanisms regulating bone expansion. Finally, our model provides a powerful tool for investigating
the effects of continuous Gs-GPCR signaling on dynamic bone growth and remodeling.  2010 American Society for Bone and Mineral
Research.
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Introduction
O
steoporosis affects over 10 million people in the United
States and contributes to1.5 millionfractures each year.
(1) A
crucial determinant of osteoporosis and fracture risk in adults is
thought to be the acquisition of peak bone mass during child-
hood and puberty.
(2–4) Osteoblasts and their precursors play key
roles in regulating bone development and acquisition of peak
bone mass.
(5) Although certain G protein–coupled receptors
(GPCRs) expressed in osteoblasts [e.g., parathyroid hormone
receptor(PTHR1)
(6)andHTR1bserotoninreceptor
(7)]areinvolved
inregulatingbone mass,the exact invivo roles ofGPCRsignaling
during skeletal growth have not been clearly elucidated.
GPCRs signal through a select number of pathways, including
the Gs and Gi pathways that influence intracellular cyclic AMP
(cAMP) levels.
(8) We described a synthetic biology approach
(9) for
activating the Gs pathway that uses the strong basal Gs signaling
activity of Rs1, an engineered receptor activated solely by a
synthetic ligand (RASSL).
(10,11) RASSLs are engineered receptors
that no longer respond to endogenous hormones but can be
activated by synthetic small-molecule drugs. They have proven
useful for studying the roles of G protein signaling in complex
systems.
(12–15)
We found that when Rs1 was expressed continuously in
mouse osteoblasts from gestation until adulthood, skeletal bone
mass and trabecular bone formation were dramatically greater
than in wild-type mice.
(11) Cortical bone was lost, and serum
markers of bone turnover weregreatly increased. In addition, the
normal bone marrow space was obliterated and replaced with
small uniform cells morphologically resembling young osteo-
blasts. Incontrast,whenRs1 wasexpressed beginningat4weeks
of age, no grossly abnormal skeletal phenotype was evident
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584through 30 weeks of age. These findings suggested that
receptor-mediatedGssignalsinosteoblasts haveage-dependent
effects on bone formation. In addition, evidence from human
diseases and animal models suggest that osteoblast function is
markedly different in children than in adults.
(16–21)
In this study, we asked how the timing of Gs signaling affects
the formation of skeletal bone at different ages. We used Rs1 to
activate the Gs signaling pathway in osteoblasts in mice at
different ages in four experiments (Fig. 1). First, we identified a
window of osteoblast responsiveness to Rs1 expression by
examining when the Rs1-induced trabecular bone phenotype
begins. Second, we narrowed the window of Rs1 expression
necessary for developing the trabecular overgrowth phenotype
by delaying Rs1 expression until after birth. Third, we assessed
whether expression of Rs1 after 4 weeks of age could lead to
long-term attenuation of the Rs1 phenotype in adult mice.
Finally, we determined whether the Rs1-induced bone pheno-
type could be reversed if Rs1 expression was discontinued after
formation of the abnormal trabecular bone in adult mice. Our
findings demonstrate the utility of the Rs1 mouse model for
controlling the timing and tissue-specific activation of Gs
signaling as a way to understand the age-dependent effects
of continuous Gs signaling by GPCRs.
Methods
Animal studies
All transgenic mouse studies were approved by and performed
in accord with the Institutional Animal Care and Use Committee
and the Laboratory Animal Research Center at the University of
California, San Francisco. The ColI(2.3)-tTA/TetO-Rs1 double
transgenic mice were generated by heterozygote crosses of
mice carrying the TetO-Rs1 transgene with mice carrying the
ColI(2.3)-tTA transgene as described previously.
(11) Transgene
expression was suppressed by continuous administration of
doxycycline-impregnated mouse chow (DoxDiet 200mg/kg;
BioServ, Frenchtown, NJ, USA) during the times indicated in
Fig. 1. Transgene expression was activated by switching the mice
to regular mouse chow without doxycycline (LabDiet 5053, PMI
Nutrition, St. Louis, MO, USA) at the times indicated in Fig. 1. Full
transgene expression was expected to occur within 1.5 to
2 weeks of doxycycline withdrawal.
(12,22) Transgene expression
was verified by quantitative polymerase chain reaction (qPCR)
in representative animals from each cohort (see Figs. 1B,3 C,5 C,
and 7F). Neonatal pups analyzed in Fig. 3 were not manipulated
until the day of tissue collection to minimize any risk of maternal
distress or cannibalism. Genotyping and selection of the
appropriate ColI(2.3)
þ/Rs1
þ and control pups were done after
tissue collection, or after 4 weeks of age for adult animals. No
alterations in litter size, pup health, or maternal health were
observed in our experiments. Both males and females were
analyzed together in our experiments because no sex-
dependent differences were observed.
Geneexpression analysis was performed on RNA isolated from
the right femur or right humerus of adult experimental animals,
as indicated in each figure legend. For the experiments in Fig. 3,
both humeri from the same 4- or 5-day-old animal were
Fig. 1. TimingofRs1expressionintheColI(2.3)-tTA/TetO-Rs1mice.(A)We
usedadoxycycline-regulatedexpressionsystemtofocusontheeffectsof
basal Gs signaling induced by Rs1 expression without ligand activation.
(B) Rs1 expression was allowed by feeding the mice regular doxycycline-
free food. Six-week-old ColI(2.3)
þ/Rs1
þ mice raised on regular food (Off
Dox) had high levels of Rs1 expression. We suppressed Rs1 expression by
giving doxycycline in the mouse chow (On Dox). Mice born and raised on
doxycycline-containing food and subsequently switched to doxycycline-
freefoodat4 weeksofageshowlowbutvariablelevelsofRs1expression
at 6 weeks of age (ColI/Rs1-late). Expression levels from femora of
representative mice are shown. Portions of this figure use RNA samples
from mice used in Fig. S5 as published.
(11) Values are mean 1S Do f
technicaltriplicates.(C–G)Thepatternofdoxycyclinefoodadministration
and Rs1 expression for each experimental manipulation is indicated in
gray. (C) ColI(2.3)
þ/Rs1
þ mice: Rs1 expression was allowed from gestation
through adulthood by feeding the pregnant mothers and their pups
regular chow. (D) ColI/Rs1-late mice: Rs1 expression was suppressed
through the first 4 weeks of development by feeding doxycycline chow
to mothers during mating and to their pups after weaning. We switched
the mice to regular chow at 4 weeks of age. (E) ColI/Rs1-early mice: Rs1
expression was allowed after birth by feeding the mother doxycycline
chow from mating until delivery. The nursing mothers were switched to
regular chow at delivery. ( F) ColI/Rs1–1week mice: Rs1 expression was
allowed until 1week of age by feeding the mothers regular chow from
mating until 1week after birth. The nursing mothers were switched to
doxycycline chow to suppress Rs1 expression in the nursing pups.
Weaned animals were maintained on doxycycline chow. (G) ColI/Rs1–
4weekmice:Rs1expressionwasallowedfromgestationthrough4weeks
of age by feeding mothers regular chow from mating through weaning.
The pups were given regular chow until 4 weeks of age. Rs1 expression
then was suppressed by switching the pups to doxycycline chow.
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dissected away from surrounding soft tissue and frozen in liquid
nitrogen. Bones for each experiment were batch processed by
crushing (multisample Bio-Pulverizer, Research Products Inter-
national, Mt. Prospect, IL, USA) followed by homogenization
(4.5mm Tissue Tearor, Research Products International) in
RNAStat-60 (Iso-Tex Diagnostics, Friendswood, TX, USA). cDNA
was generated using the SuperScript III First Strand Synthesis kit
(Invitrogen, Carlsbad, CA, USA) as directed by the manufacturer.
Expression was assayed using SybrGreen primers as described
previously,
(11) Sybr green primers for RANKL (forward¼TTG-
CACACCTCACCATCAAT; reverse¼TCCGTTGCTTAACGT-CATGT)
and OPG (forward¼CAGAGACCAGGAAATGGTGAA; rever-
se¼AAGCTGCTCTGTGGTGAGGT) or TaqMan primers
(Mm99999913_g1 for GAPDH, Mm00484036_m1 for cathepsin
K, Mm0081666_g1 for collagen 1a1, Mm00504574_m1 for
osterix, and Mm00501578_m1 for runx2). All samples were
assayed in technical triplicate, and expression levels were
normalized toGAPDH.AllqPCRreactions wererunonanApplied
Biosystems (Foster City, CA, USA) 7900HT real-time thermocycler.
Bone densitometry and imaging
Mice identified for dual-energy X-ray absorptiometry (DXA) to
measure whole-body areal bone mineral density (aBMD) were
anesthetized with inhaled isofluorane (1.5% to 2% in oxygen)
and scanned on a GE Lunar Piximus2 (Madison, WI, USA) at
predetermined times. Mice that underwent whole-mouse or ex
vivo femur micro-computed tomographic (mCT) scans were
sacrificed before scanning on a Scanco vivaCT-40 mCT scanner
(SCANCO, Wayne, PA, USA). Femora for ex vivo scanning were
fixed in 10% neutral buffered formalin (Fisher Scientific, Fairlawn,
NJ, USA) for 24 hours and stored in 70% ethanol. Images were
obtained at an X-ray energy of 55kV, with a voxel size of 76 or
10.5mm and integration times of 200 or 1000 ms for whole-body
images or ex vivo femur images, respectively. Because of age-
dependent variations in bone mineralization, segmentation
values for whole-animal mCT were determined empirically as 0.1/
1/100 (gauss sigma/gauss support/threshold in mg HA/ccm) for
newbornsand1.5-week-oldanimals.Segmentationvaluesof0.7/
1/250 were used for the ex vivo femur CT scans.
Bone histology
Mice identified for histomorphometry were injected with 15mg/
kg calcein (Sigma-Aldrich, St. Louis, MO, USA) 7 days before
harvesting and with 90mg/kg xylenol orange (Sigma-Aldrich)
2 days before harvesting to label areas of active bone
mineralization. Harvested bones were processed for von Kossa
staining, tartrate-resistant acid phosphatase (TRAP) immunos-
taining, and fluorescence microscopy as described previously.
(11)
Bones for hematoxylin and eosin staining were decalcified for 12
to 48 hours in 10% EDTA/PBS before paraffin embedding,
sectioning, and staining by the Gladstone Histology Core.
Serum analysis
Blood was collected from euthanized mice by cardiac puncture
and processed in MicroTainer serum separator tubes according
to the manufacturer’s instructions (BD Biosciences, San Jose, CA,
USA). Routine blood analysis was carried out by Antech
Diagnostics (Irvine, CA, USA). Serum osteocalcin and pyridinoline
measurements were carried out using the mouse osteocalcin EIA
Kit BT-470 from BTI (Stoughton, MA, USA) and the MetraBiosys-
tems SerumPYD Kit 8019 (Palo Alto, CA, USA) according to
manufacturers’ directions.
Statistical analysis
Two-tailed Student’s t tests with unequal variances were
performed using Microsoft Excel 2003. ANOVA analysis was
performed using JMP8 (Version 8.0, SAS Institute, Cary, NC, USA).
Results
Rs1-induced bone formation in early postnatal
skeletal growth
We previously reported that Rs1-induced basal Gs signaling in
osteoblasts of ColI(2.3)
þ/Rs1
þ mice increased trabecular bone
and decreased cortical bone in lesions reminiscent of fibrous
dysplasiaofthebone.
(11)Inaddition,increasesinthewhole-body
BMDofColI(2.3)
þ/Rs1
þmiceexpressingRs1weredetectableonly
after 3 weeks of age.
(11) To determine if Rs1-induced trabecular
bone formation occurs earlier in postnatal growth and if Rs1
affects the patterning of the normal bone structures, we used
mCT, histology, and gene expression to analyze bone formation
in young mice expressing Rs1 from gestation.
mCT imaging showed no gross differences in skeletal
patterning or overall bone shape before 1.5 weeks of age (see
Fig. 2). At 1.5 weeks of age, small changes in bone structure were
observed, primarily in the long bones of the mice. Since mCT
analysis in prepubertal mice is complicated by rapidly changing
bone mineral content during postnatal growth, we assessed
bone structure by performing histology on femora from
ColI(2.3)
þ/Rs1
þ mice at 4 to 6 days after birth.
Histology revealedthatfemora oftheColI(2.3)
þ/Rs1
þ micehad
normal periosteum, bone collar, and bone marrow cells through
Fig. 2. Mice expressing Rs1 from gestation showed no gross skeletal
patterning defect. Note the subtle changes in bone size in the 1.5-week-
old ColI(2.3)
þ/Rs1
þ mice with mild thickening in the diaphyses of the
femora and humeri (arrows). Scale bar¼5mm.
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Rs1 expression (see Fig. 3C). However, by 5 days of postnatal
growth, femora from the ColI(2.3)
þ/Rs1
þ mice showed increased
trabecular bone, decreased cortical bone, and narrowed bone
marrow space (see Fig. 3A, B). By 6 days, the femora fully
recapitulated the trabecular bone replacement of the entire
bone as described in 3-week-old ColI(2.3)
þ/Rs1
þ mice
(11) (see
Fig. 3A).
Gene expression analysis from 4 day old ColI(2.3)
þ/Rs1
þ and
control mice was used to examine the expression of genes
marking mature (osteocalcin and collagen I) and immature
osteoblasts (osterix and runx2) (see Fig. 3D–G). Osteocalcin levels
were unchanged in the 4-day-old ColI(2.3)
þ/Rs1
þ mice. However,
collagen I, osterix, and runx2 all showed increased levels in the
ColI(2.3)
þ/Rs1
þ mice despite the lack of an obvious histologic
phenotype. By day 5, expression of all these genes was greater in
the bones of ColI(2.3)
þ/Rs1
þ mice than in those of wild-type
mice. In addition, expression levels of cathepsin K (a marker of
osteoclasts) as well as osteoprotegerin (OPG) and RANKL (both
regulators of osteoclast activity) were increased in the ColI(2.3)
þ/
Rs1
þ mice at both 4 and 5 days of age. The RANKL/OPG ratios,
used as ameasure of osteolytic balance,
(23) were not significantly
different in the ColI(2.3)
þ/Rs1
þ mice between days 4 and 5 (1.25
versus 1.11, respectively).
These results show that continuous Gs signaling induced by
Rs1 in osteoblasts leads to increased trabecular bone formation
Fig. 3. Rs1-induced bone formation occurs between days 4 to 6 in postnatal skeletal growth. (A) Representative hematoxylin and eosin histology of
paraffin-embeddeddecalcifiedfemursectionsof4-,5-,and6-day-oldand3-week-oldColI(2.3)
þ/Rs1
þorcontrol(wild-typeorsingle-transgenic)mice.Note
the increased trabecular bone, decreased cortical bone, and narrowed bone marrow space in the day 5 and 6 femora reminiscent of the changes seen in
the 3-week-old mice. Skeletal muscle was left in place for 4- and 5-day-old samples to preserve adjacent bone morphology during processing.
p¼periosteum; s¼bone marrow space; c¼cortical bone; t¼trabecular bone; m¼skeletal muscle. Scale bar¼1mm. (B) High-magnification images of
day 5 control and ColI(2.3)
þ/Rs1
þ femora (boxed regions in panel A) showing the increased trabecular bone resulting from Rs1 expression. (C–J) Relative
expression levels by quantitative PCR of whole humeri from ColI(2.3)
þ/Rs1
þ (filled bars) and control littermates (open bars). For the quantitative PCR, n¼6
controland6mutant4-day-oldmice;n¼6controland5mutant5-day-oldmice.Expressionlevelsweredeterminedintechnicaltriplicatesforeachmouse
and normalized to GAPDH. Values are mean 1 SEM. a: p<.05 versus controls; b: p<.1 versus controls. (C) Rs1 expression in 4- and 5-day-old ColI(2.3)
þ/
Rs1
þ pups and littermate controls. Five-day-old ColI(2.3)
þ/Rs1
þ pups from mothers fed doxycycline-containing food (day 5, on dox) demonstrate
suppression of Rs1 expression, indicating that doxycycline fed to nursing mothers crossed adequately into breast milk. n¼4 ColI(2.3)
þ/Rs1
þ pups
maintained on doxycycline. (D, E) Osteocalcin and collagen I expression, markers of mature osteoblasts. ( F, G) Osterix and runx2 expression, markers of
immature osteoblasts. (H–J) Cathepsin K, OPG, and RANKL expression, markers of osteoclastogenesis.
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of early osteoblast markers. In contrast, the increased bone
formation was not accompanied by a change in the RANKL/OPG
ratios.
Delayed timing of Rs1 expression
The prior results show that Rs1 expression occurs before
development of the trabecular bone phenotype at day 5 of
postnatal growth. In addition, Rs1 expression after 4 weeks of
age (ColI/Rs1-late mice, Fig. 1D) led to no grossly abnormal bone
phenotype in adult mice,
(11) suggesting a window of sensitivity
to Rs1 signaling between postnatal day 5 and 4weeks of age. We
used the tetracycline transactivator system to limit Rs1
expression to narrow the window of maximal osteoblast
sensitivity to Rs1 signaling.
TodetermineifRs1expressionduringthelateprenataltoearly
postnatal period is required to increased trabecular bone
formation in adult mice, we suppressed Rs1 expression through
birth (ColI/Rs1-early mice, Fig. 1E) by feeding pregnant mice
doxycycline-containing chow. Pups and their nursing mothers
were removed from doxycycline on the day of delivery to allow
Rs1 expression. The pups were followed by serial whole-body
BMD scans through the first 9 weeks of postnatal life. The ColI/
Rs1-early mice developed the trabecular overgrowth phenotype,
but to a milder degree than in the ColI(2.3)
þ/Rs1
þ mice
expressing Rs1 from gestation (see Fig. 4A), as assessed by
whole-body BMD.
To further define the timing of Rs1 expression necessary to
develop and maintain the bone-overgrowth phenotype, we
examined ColI/Rs1–1week mice in which Rs1 expression was
limited to gestation through the first week of postnatal life (see
Fig. 1F). These mice did not develop the increased trabecular
bone as adults or show whole-body BMDs different from wild-
type littermate controls (see Fig. 4B).
These results indicate that maximal Rs1-induced bone
formation in an adult mouse is strongly influenced by early
Rs1 expression during prenatal gestation and early postnatal
development. Furthermore, discontinuing Rs1 expression early
in postnatal growth but after the trabecularization has been
initiated resulted in normal BMD in adult animals, suggesting
that growing bone could recover from the Rs1-induced
abnormal bone formation if Rs1 expression was discontinued
early.
Long-term expression of Rs1 in adult mice
The results for the ColI/Rs1-early mice and our prior observation
that ColI/Rs1-late mice (see Fig. 1D) did not develop the grossly
abnormal bone through 30 weeks of age
(11) suggested that the
ability of Rs1 to induce trabecular bone formation decreased as
the mice aged despite detectable Rs1 expression in bone. To
identify whether the ColI/Rs1-late mice remained free of the
bone overgrowth phenotype as the mice aged, we preformed
long-term follow-up on these mice through 60 weeks of age.
The ColI/Rs1-late mice showed no significant increases in
whole-body BMD until 40 weeks of age. Between 40 and
60 weeks of age, all the ColI/Rs1-late mice showed increased
trabecular bone, but only 50% of the mice developed a whole-
body BMD greater than 2 SD above the peak wild-type BMD (see
Fig.5A).Sitesofabnormalboneformationoftenwereadjacentto
regions of normal bone and occurred as distinct nodules (see
Fig. 5B). Serum osteocalcin (a marker for bone formation) was
increased slightly at 20 and 55 weeks, but serum pyridinoline
cross-links (a marker for bone resorption) did not change (see
Fig. 5D). These results suggest that Rs1 activity in adult bone
primarily increases bone formation over bone resorption. No
significantdifferencesinserumcalciumorphosphatelevelswere
detected at either 20 or 55 weeks (data not shown).
mCT analysis on femora from 20-week-old ColI/Rs1-late mice
showed a subtle expansion of trabecular bone starting at the
femoral metaphyses. The increase in trabecular bone was
accompanied by a loss of endocortical bone and narrowing of
the bone marrow space in the ColI/Rs1-late mice (Fig. 6). Double
fluorochrome labeling to assess bone mineralization showed an
increase in disorganized trabecular bone formation in the 20 and
55-week-old ColI/Rs1-late mice. In addition, TRAP staining
showed a localized increase in osteoclast-like cells within the
regions of disorganized trabecular bone in the ColI/Rs1-late mice
at both ages despite the normal systemic levels of pyridinoline
crosslinks (see Fig. 5D). Von Kossa staining showed that the
regions of disordered trabecular bone in the ColI/Rs1-late mice
shared similar histologic features with the abnormal bones in the
ColI(2.3)
þ/Rs1
þ mice expressing Rs1 from gestation, including a
decrease in bone marrow cells and an increase in small
osteoblast-like cells by morphology.
(11)
These results indicate that delaying Rs1 expression until
4 weeks of age leads to long-term attenuation of the Rs1-
induced phenotype. However, a subtle increase in bone
formation could be detected as early as 20 weeks of age.
Although the bone-overgrowth phenotype was clearly evident
by 40 to 60 weeks of age, bone formation was significantly
slower in the ColI/Rs1-late mice than in the ColI(2.3)
þ/Rs1
þ mice
expressing Rs1 from gestation. In addition, the new trabecular
bone appeared to originate from sites of existing trabecular
bone, such as at the femoral metaphyses, rather than as de novo
Fig. 4. Delayed Rs1 expression leads to a milder bone overgrowth
phenotype. (A) ColI/Rs1-early mice in which Rs1 expression began after
birthhave intermediatewhole-bodyBMDas comparedto ColI(2.3)
þ/Rs1
þ
mice expressing Rs1 from gestation and similarly treated wild-type
littermates. n¼4 WT (–dox at birth), 10 WT (–dox), 10 ColI(2.3)þ/Rs1þ
(–dox), and 6ColI/Rs1-early (–dox at birth) at each time point. Values are
mean 1 SD. a: p<.05 versus ColI/Rs1-early; b: p<.01 versus WT; c:
p<.001 versus ColI/Rs1-early; d: p<.001 versus WT. (B) BMD in ColI/Rs1–
1week mice and wild-type littermates indicate that the abnormal bone
phenotype is not maintained once Rs1 expression is discontinued. n¼9
WT and 5 mutant mice per time point. Values are mean 1 SD. e: p<.05
versus WT.
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the mid-diaphysis.
Reversibility of the Rs1-induced trabecular bone
formation
The absence of an increased BMD in the ColI/Rs1–1week mice
indicated that the Rs1-induced trabecular bone growth might be
reversible if Rs1 expression were discontinued before weaning. To
determine if established Rs1-induced bone lesions in adult mice
also could be reversed and if continued activation of the Gs
signaling pathway by Rs1 was required to maintain the abnormal
increase in trabecular bone, we assessed mice in which Rs1
expression was suppressed after 4 weeks of age (ColI/Rs1–4week
mice, see Fig. 1G). The ColI/Rs1–4week mice developed the
abnormal increase in trabecular bone, decrease in cortical bone,
andlossofbone marrow space during the first 4 weeks of life. After
this bone phenotype was established, we suppressed Rs1
expression by feeding the mice doxycycline-containing chow.
ColI/Rs1-4week femora examined over the next 32 weeks
showed a gradual decrease in trabecular bone and a restoration
of cortical bone and the bone marrow space (see Fig. 7A, B).
Double fluorochrome labeling showed that the normal linear
bone mineralization pattern gradually returned as the trabecular
bone disappeared (see Fig. 7C). TRAP staining also indicated a
decreaseinosteoclastlineagecellswithinthebones(seeFig.7D).
Although the overall shape of the bone did not fully return to
normal by 36 weeks of age, the gross deformation originally
present in the 4- to 6-week-old mice was significantly reversed.
Histology on undecalcified bone sections (see Fig. 7E) indicated
the return of a normal hematopoietic bone marrow space. In
addition, we observed a rapid decrease in the number of
morphologically small osteoblast-like cells previously identified
in the ColI(2.3)
þ/Rs1
þ trabecular overgrowth bones.
BMDs of individual mice at the start of this experiment at
4 weeks of age were variable (see Fig. 7G), but all BMDs declined
or stabilized after Rs1 expression was suppressed. In mice with a
starting 4week BMD of greater than 3 SD above the mean wild-
type BMD, whole-body BMDs gradually decreased over 26
weeks, correlating with the reversal of the trabecular bone
phenotype observed by mCT imaging (see Fig. 7H). Serum
calcium and phosphate levels at 20 and 36 weeks were
similar between wild-type and ColI/Rs1–4week mice (data not
shown). Three-week-old ColI/Rs1–4week mice (before starting
doxycycline) showed higher levels of serum osteocalcin but not
pyridinoline cross-links than age-matched control littermates
(359.20 45.91 versus 257.50 50.15ng/mL, p¼.01, and
1.42 0.31 versus 1.53 0.42nmol/L, p¼.6, respectively; n¼5
mutants and n¼5 controls). Osteocalcin and pyridinoline
cross-link levels were both normal in the 20- to 25-week-old
ColI/Rs1–4week mice compared with age-matched control
littermates (78.36 44.78 versus 62.91 35.22ng/mL, p¼.5,
and 1.53 0.63 versus 1.81 0.89nmol/L, p¼.6, respectively;
n¼6 mutants and n¼5 controls).
These results indicate that the abnormal trabecular bone
formation and loss of cortical bone observed in the ColI(2.3)
þ/
Fig. 5. Expression of Rs1 after 4 weeks of age leads to long-term attenuation of the Rs1 phenotype. (A) Longitudinal whole-body aBMD showed a
significant increase in average BMD as the ColI/Rs1-late mice aged. The dotted line indicates 2 SD above the WT BMD at 30 weeks (0.0613g/cm
2). n 4
mice for each time point. Values are mean 1 SD. a: p<.05 versus WT. (B) DXA image of a representative 60-week-old ColI/Rs1-late mouse showing
isolated regions of subtle increased bone formation. RH¼right humerus; LH¼left humerus; LS¼lumbar spine. (C) Rs1 expression in RNA isolated from
whole humeri from representative ColI/Rs1-late mice showing low expression at 30 weeks (before the phenotype is evident) and higher expression at
60 weeks (when bone overgrowth is evident). Values represent mean 1 SD of technical triplicates. (D) Serum analysis of osteocalcin (a marker of bone
formation) and pyridinoline cross-links (a marker of bone resorption) in ColI/Rs1-late mice. At 20 weeks, n¼8 mutants, 6 WT; at 55 to 60 weeks, n¼4
mutants, 4 WT. Values are mean 1 SD. a: p<.05 versus WT; b: p<.01 versus WT.
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þmiceexpressingRs1fromgestationcanbereversedinadult
mice by suppressing the expression of Rs1. Although the
bone did not return fully to a normal structure at the end of
the36weekexperiment,ourresultsdemonstratethatadultbone
maintains a high degree of plasticity for bone remodeling.
Discussion
In this study, we applied an engineered receptor approach and
mouse model of temporally regulated osteoblast-specific Gs
activation by the Rs1 RASSL to identify how Gs signals regulate
Fig. 7. The Rs1-inducedtrabecularbonephenotypeis reversible. (A, B) Representative longitudinal(A) and transverse (B) mCT imagesof femora from ColI/
Rs1–4week mice expressing Rs1 from gestation until 4 weeks of age, showing the loss of accumulated trabecular bone and return of the bone marrow
space and cortical shell after Rs1 expression has been discontinued. A femur from a 20-week-old WT mouse is shown for comparison. t¼trabecular bone;
c¼cortical bone; s¼bone marrow space. Scale bar¼1mm. (C) Fluorescent imaging of double-labeled bone showing the return of linear, orderly bone
mineral apposition (green¼calcein; orange¼xylenol orange) similar to that seen in WT animals. Scale bar¼10mm. (D) TRAP staining shows a significant
decrease in osteoclast lineage cells (pink) as the trabecular bone overgrowth resolves. Scale bar¼100mm. (E) von Kossa staining showing the return of
normal-appearing trabeculi and bone marrow cells, similar to that seen in WT animals. Scale bar¼100mm. ( F) Rs1 expression levels in whole humeri
isolated from ColI/Rs1–4week mice shows rapid suppression after doxycycline is started at 4 weeks of age. Representative mice are shown for each
timepoint. Values are mean 1 SD of technical triplicates. (G) Plots of whole-body BMD of six representative ColI/Rs1-4week mice (colored lines) and one
WTmouse(black,bottomline)indicatevariationinthedegreeofboneaccumulationatthestartofthestudyat4weeks.Allmutantmiceshoweddecreases
in their BMD after Rs1 expression was discontinued. At 4 weeks, mice were stratified into two groups: BMD < 3 SD above the average WT BMD (0.0521g/
cm
2,as indicatedby thedottedline;WTaverage¼0.0403 0.0039g/cm
2) andBMD>3 SDabovetheaverageWTBMD. Micein group2 wereselectedfor
pooled analysis in panel H.( H) Average whole-body BMD for group 2 mice (as determined in panel G) showed a continuous decline after Rs1 expression
was discontinued. The number of animals meeting the criteria for group 2 at 4, 6, 9, 13, 18, 20, 25, and 30 weeks: WT: 16, 10, 9, 11, 12, 7, 4, and 4; ColI/Rs1–
4week: 7, 6, 5, 6, 10, 8, 6, and 5. Values are mean 1 SD. a: p<.05; b: p<.005; c: p<.001 versus WT.
Fig. 6. Representative mCT images of femora in longitudinal and transverse mid-diaphysis sections of age- and sex-matched mice show a delayed but
gradualincreaseintrabecularboneandlossofcorticalboneintheColI/Rs1-latemice.Scalebar¼1mm.Doublefluorochromelabeling(middlepanels)with
calcein (green) and xylenol orange (orange) demonstrated disordered bone formation in the areas of increased trabecular bone. Scale bar¼10mm. TRAP
staining(pink),indicativeof osteoclast-lineagecells, is increasedwithintheregionsof expanded trabecularbonein ColI/Rs1-latemice. Scalebar¼100mm.
VonKossastainingshowstheincreasedtrabecular boneandlossofnormalbonemarrowcells(scalebar¼100mm).c¼corticalbone;t¼trabecularbone;
s¼bone marrow space.
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experiments on the effects of Rs1 expression without ligand
activation because Rs1 has a high degree of basal Gs signaling
activity.
(10,11) The double-transgenic ‘‘Tet-Off’’ strategy allowed
doxycycline-dependent regulation of Rs1 expression and hence
control of the basal Gs signaling activity of Rs1. Our studies are
especially relevant to the long-term effects of continuous Gs
signaling by GPCRs in osteoblasts. We found that the Rs1
phenotype developed rapidly between postnatal days 4 and 6,
that progressively delayed Rs1 expression resulted in decreased
Rs1-induced bone formation, and that the Rs1-induced bone
growth and deformities were dramatically reversed when Rs1
expression was suppressed in adult mice.
Our findings with the ColI/Rs1-early and ColI/Rs1-late mice
indicate that osteoblasts from young animals and osteoblasts
from older animals both form trabecular bone in response to Gs
activation by Rs1. However, delaying Rs1 expression leads to
quantitatively different amounts of bone formation. Prior results
suggested that Rs1 expression may be lower in adult animals,
(11)
possibly as a result of age-dependent changes in collagen I
promoter methylation.
(24) Age-dependent decreases in sensitiv-
ity to Gs signaling or cAMP also may contribute because
osteoblast adenylyl cyclase activity decreases with age.
(25)
A number of GPCRs are expressed in bone, including the
parathyroid hormone/parathyroid hormone–releasing peptide
(PTH/PTHrP) receptor,
(26) endothelin receptor,
(27) prostaglandin E2
receptor,
(28) adrenaline receptor,
(29,30) thyroid-stimulating hormone
receptor,
(31) a n dt h eH T R 1 bs e r o t o n i nr e c e p t o r .
(7) Age-dependent
activity of these receptors or their ligands may allow other GPCR
signaling pathways to modulate the bone-formation effects of Rs1.
Activation of the Gi signaling pathway by the Ro1 engineered
RASSL
(22) or other GPCRs
(7,32) is associated withdecreased trabecular
bone formation, suggesting that the Gi pathway could dampen the
bone-formation effects of Gs signaling in older animals. In addition,
activation of the Gq pathway leads to osteopenia and may
desensitize osteoblasts to Gs signaling.
(33,34) Since the PTH receptor
signals through Gs,G i,a n dG q, this suggests that the non-Gs
pathways balance the Gs-mediated trabecular bone-formation
process. The interactions between the different GPCRs expressed
in an osteoblast also may account for the phenotypic variability we
observed between individual mice.
Age-dependent increases in osteoclast formation
(39) also may
contribute to the decreased Rs1-induced trabecular bone
formation we observed in adult mice. Although increased
markers of osteoclasts are evident in the ColI(2.3)
þ/Rs1
þ bone
lesions, our results indicate that osteoblast-induced osteoclast
formation does not occur during the initial formation of
abnormal trabecular bone between days 4 and 5 of postnatal
growth. Continued exposure to Rs1 activation eventually may
result in increased osteoclastogenesis driven by more mature
osteoblasts, similar to what has been reported after PTH
treatment of cultured bone marrow stromal cells.
(40) As a result,
a net increase in osteoclast formation or activity may protect
adult bones from the early effects of Rs1.
The bone-formation pattern in the ColI(2.3)
þ/Rs1
þ mice
expressing Rs1 from gestation resembles the lesions in fibrous
dysplasia patients
(35) but to a more severe degree. Clinically,
fibrous dysplasia lesions are heterogeneous with abnormal and
normal trabecular bone, often at distinct anatomic sites.
(36) The
ColI/Rs1-late mice in our study particularly resemble this type of
lesion, suggesting that the heterogeneous nature of fibrous
dysplasia may be a result of changes in osteoblast sensitivity
to Gs signaling. This idea that osteoblasts in fibrous dysplasia
lesions may have reacquired the characteristics of a perinatal
osteoblastcorrelateswithsuggestionsthatfibrousdysplasiamay
be a stem cell disease.
(37) Furthermore, a non-cell autonomous
mechanism may contribute to the development of fibrous
dysplasia lesions
(38) and may similarly modify the osteoblast
response to Rs1-mediated Gs activation in an age-dependent
manner.
Our finding that Rs1-induced trabecular bone formation
occurs during a discrete window of days 4 to 5 of early postnatal
growth was surprising because the ColI(2.3) promoter is active
starting before birth,
(41,42) and Rs1 expression was detectable
before any bone changes were evident on histology. This result
suggests that the early developmental processes that establish
bone patterning and structure prior to postnatal day 4
(43) are not
significantly affected by Gs signaling. Since the distinct transition
atdays 4to5ofpostnatalgrowth isassociatedwithearlyweight-
bearing activity and the appearance of the secondary
spongiosum in mice,
(44,45) Gs signaling may act at this point
to promote trabecular bone expansion. In contrast, Gi signaling
appears to have roles in neonatal bone formation. Earlier results
using the ColI(2.3) promoter to express a Gi coupled engineered
receptor in osteoblasts before birth resulted in embryonic
lethality.
(22) In addition, cre-mediated inactivation of the
osteoblast GNAS gene encoding the Gsa subunit resulted in
severe neonatal skeletal malformations and decreased trabe-
cular bone.
(32) These findings suggest that the roles of Gs
signaling may shift during early skeletal development from
maintenance of the osteoblast niche to driving expansion of
trabecular bone.
Our result that the Rs1-induced trabecular bone formation is
largely reversible has several important implications. First, bone
formation during prepubertal growth can have long-term effects
on adult bone, but that bone remodeling may temper these
effects.Recentanimalstudies
(46)andclinicalstudiesinchildren
(2)
suggest that exercise during childhood can lead to an increase in
bone mass that persists with age. The unique nature of the
prepubertal skeletal system is further emphasized in that a
number of human diseases affecting G protein signaling in the
bone have a tendency to present during childhood with long-
term sequela in adults.
(47–49) However, very early changes in
bone formation, as indicated by the ColI/Rs1–1week mice, may
not have long-term effects on the skeleton. Second, continuous
activation ofthe Gs signalingpathway isrequired tomaintain the
increase in trabecular bone induced by Rs1. Clinical studies show
that bone formed by recombinant PTH (teriparatide) is lost
rapidly unless an antiresorptive medication is used when PTH is
discontinued.
(50,51) Our results indicate that the changes in bone
mass are more likely due to changes in Gs pathway activation
rather than to the signaling properties of a specific receptor (e.g.,
PTHR1).Finally,ourresultsshowthatnormalbonehasadramatic
ability to repair itself once an insult is discontinued. Since the
ColI(2.3)
þ/Rs1
þ mice share strong histologic resemblance to
polyostotic fibrous dysplasia
(35) and the bone lesions in McCune-
AGE-DEPENDENT EFFECTS OF GS GPCR SIGNALING Journal of Bone and Mineral Research 591Albright syndrome,
(35) our results suggest that inhibiting the Gs
signaling pathway maybe aneffective strategy fortreating these
patients. Our findings also suggest that bones retain information
about their normal shape and structure independent of the
capacityforskeletalexpansion,whichcouldbeusedduringbone
remodeling to restore normal bone structure.
In conclusion, bone formation is a highly plastic process with a
complex array of signaling inputs that ultimately determine peak
bone mass and normal bone architecture. Understanding how
bone tissue can be grown and re-formed may reveal basic
properties of bone that will be useful in bone regeneration and
repair. Our model provides a dramatic example of how
osteoblast-specific hormone signaling can completely reshape
bone architecture in a reversible fashion. Insight into how
hormone signals can alter morphology will help in the
development of new ways to modulate the signaling of
endogenous GPCRs to reshape bone in a therapeutic setting.
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